International Stem Cell Corporation (OTCBB: ISCO) today announced
that it will hold a conference call and webcast on Thursday, November
17, 2011 at 1:00 p.m. Eastern (10:00 a.m. Pacific). President and Chief
Operating Officer Kurt May and Co-Chairman Ken Aldrich will provide an
update on the business, including a discussion of recently announced
third quarter results.
Individuals interested in listening to the conference call may do so by
dialing 877-407-8033 for domestic callers, or 201-689-8033 for
international callers, or from the webcast on the investor relations
section of the Company's Web site at www.intlstemcell.com.
A telephone replay will be available approximately one hour after the
conclusion of the call by dialing (877) 660-6853 for domestic callers,
or 201-612-7415 for international callers, and entering the account
code: 286 and the Conference ID: 383602. The webcast will be available
on the Company's Web site for 60 days following the completion of the
call.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells (hpSCs) and the
development and commercialization of cell-based research and cosmetic
products. ISCO's core technology, parthenogenesis, results in the
creation of pluripotent human stem cells from unfertilized oocytes
(eggs). hpSCs avoid ethical issues associated with the use or
destruction of viable human embryos. ISCO scientists have created the
first parthenogenic, homozygous stem cell line that can be a source of
therapeutic cells for hundreds of millions of individuals of differing
genders, ages and racial background with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true stem
cell bank, UniStemCell™. ISCO also produces and markets specialized
cells and growth media for therapeutic research worldwide through its
subsidiary Lifeline Cell Technology, and cell-based skin care products
through its subsidiary Lifeline Skin Care. More information is available
at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click
on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
LHA
Don
Markley
310-691-7100
dmarkley@lhai.com